Patients with both high
tumor mutation burden and high PDL - 1 positive status had a 75 percent response rate compared with a 16 percent response rate to immunotherapy among patients with low mutation burden and low PDL - 1.
«The good news is that we discovered that a subset of patients who had both high
tumor mutation burden and high PDL - 1 positive status did experience a significant benefit from immunotherapy,» says Carbone.
«This study is an important step toward understanding the impact of
tumor mutation burden and PDL - 1 in immunotherapy response.
Not exact matches
«In this study we've shown five distinct ways — by quantifying
tumor burden, identifying disease subtype, cataloging
mutations, predicting transformation and providing early warnings of recurrence — that circulating
tumor DNA can yield potentially clinically useful information,» said Diehn.
In one report, a patient with an L576P KIT
mutation in whom imatinib therapy had previously failed experienced marked reduction in
tumor burden in response to dasatinib treatment.
The «mutational
burden,» or the number of
mutations present in a
tumor's DNA, is a good predictor of whether that cancer type will respond...